BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15743924)

  • 1. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
    Lanz TA; Hosley JD; Adams WJ; Merchant KM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
    Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
    Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
    J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat.
    Best JD; Jay MT; Otu F; Churcher I; Reilly M; Morentin-Gutierrez P; Pattison C; Harrison T; Shearman MS; Atack JR
    J Pharmacol Exp Ther; 2006 May; 317(2):786-90. PubMed ID: 16443723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
    Lanz TA; Karmilowicz MJ; Wood KM; Pozdnyakov N; Du P; Piotrowski MA; Brown TM; Nolan CE; Richter KE; Finley JE; Fei Q; Ebbinghaus CF; Chen YL; Spracklin DK; Tate B; Geoghegan KF; Lau LF; Auperin DD; Schachter JB
    J Pharmacol Exp Ther; 2006 Nov; 319(2):924-33. PubMed ID: 16920992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor.
    Grimwood S; Hogg J; Jay MT; Lad AM; Lee V; Murray F; Peachey J; Townend T; Vithlani M; Beher D; Shearman MS; Hutson PH
    Neuropharmacology; 2005 Jun; 48(7):1002-11. PubMed ID: 15857627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
    Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
    J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures.
    Lanz TA; Fici GJ; Merchant KM
    J Pharmacol Exp Ther; 2005 Jan; 312(1):399-406. PubMed ID: 15340006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
    Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
    J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain.
    Goggi JL; Lewis HD; Mok J; Harrison T; Shearman MS; Atack JR; Best JD
    J Neurosci Methods; 2006 Oct; 157(2):246-52. PubMed ID: 16859750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice.
    Lanz TA; Himes CS; Pallante G; Adams L; Yamazaki S; Amore B; Merchant KM
    J Pharmacol Exp Ther; 2003 Jun; 305(3):864-71. PubMed ID: 12626636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
    Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
    J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
    Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
    Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.